Clinical Trial Detail

NCT ID NCT02890329
Title Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

acute myeloid leukemia

myelodysplastic syndrome

Therapies

Decitabine + Ipilimumab

Age Groups: adult senior

No variant requirements are available.